pharmaphorum
OCTOBER 27, 2020
Merimepodib – originally developed by Vertex Pharma – is an inhibitor of the enzyme inosine monophosphate dehydrogenase (IMDPH), which is required for the synthesis of viral RNA. Merimepodib is the subsidiary’s primary asset, and the biotech now says it is to offers to acquire or license the drug. Image credit: Rocky Mountain Labs/NIH.
Drug Discovery World
MARCH 7, 2023
She founded Neuroute in 2019, with the aim of empowering patients from diverse backgrounds to participate in drug trials. Prior to Twist Bioscience, she worked at Agilent Technologies and at the University of Houston developing DNA and RNA parallel synthesis processes on solid support.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
JANUARY 17, 2024
6 Genomic (DNA) analysis provides information on past mutations acquired during the evolutionary history of the tumour, whereas transcriptomic (RNA) analysis provides accurate phenotypic information of the tumour at the time of sampling 10 , thus CTCs provide prospective information on the evolving tumour or metastasis. 22 Ring et al.,
Drug Discovery World
OCTOBER 6, 2022
Before drugs make it to market they have to pass through a gauntlet of stages involved in clinical trials. As such, patient selection for clinical trials has become an increasingly critical consideration for drug trial success. About the author . Jarret Glasscock is a geneticist and computational biologist.
Pharmaceutical Technology
APRIL 27, 2023
GlobalData pharmaceutical analysts project that RNA-based gene therapies for oncology will grow from zero in 2022 to $4.6 Makowiecki says the same benefits apply to the development and manufacture of RNA-LNPs as in other biopharmaceutical manufacturing, while accommodating for their unique characteristics. billion by 2028.
Expert insights. Personalized for you.
98 
Let's personalize your content